CENTRAL NERVOUS SYSTEM ANTIGEN’S EPITOPES SELECTION, WHICH TAKE PART IN MULTIPLE SCLEROSIS PATIENTS AUTOIMMUNE REACTIONS, AS A WAY OF A SPECIFIC TOLEROGENITY CREATION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To determine the central nervous system (CNS) peptide epitopes that take part in multiple sclerosis (MS) immune response, and taking into consideration the literature, we selected CNS peptides that most likely participated in MS immune response: MBP1 (83-99), MBP2 (111-129), MBP3 (146-170), PLP, and MOG. We estimated the specific activation of serum T-cells by the level of detected cytokines in 6 MS patients: 3 - with relapsing-remitting MS (RRMS), 2 - primary progressive MS (PPMS), 1 - secondary progressive MS (SPMS). As a result we revealed that all selected peptides took part in MS immunopathogenesis: in all patients MBP1 and PLP were involved; MBP2, MBP3, and MOG - in 5 of 6 patients. In response to CNS peptides T-cells most actively produced INFg, in a less degree - IL10 and IL4. In 5 of 6 cases we found negative correlation between levels of INFg and IL10. Cytokine levels did not differ between RRMS, PPMS and SPMS. Our results confirm the immunological phenomenon of epitope spreading that affects the efficacy of MS treatment, including immunological tolerance restoration.

Full Text

Restricted Access

About the authors

G. N Bisaga

S.M. Kirov Military Medical Academy; V.A. Almazov National Medical Research Centre

V. S Chirsky

S.M. Kirov Military Medical Academy

Email: v_chirsky@mail.ru

I. A Baldueva

N.N. Petrov Research Institute of Oncology

T. L Nechaeva

N.N. Petrov Research Institute of Oncology

References

  1. Бойко А.Н., Гусев Е.И. Современные алгоритмы диагностики и лечения рассеянного склероза, основанные на индивидуальной оценке состояния пациента. Журн. неврологии и психиатрии им. C.C. Корсакова 2017; 117(2): 92-106.
  2. Бисага Г.Н., Гайкова О.Н., Онищенко Л.С. и др. Рассеянный склероз: от морфологии к патогенезу. Санкт-Петербург, 2015: 104.
  3. Xiao B.G., Huang Y.M., Link H. Tolerogenic Dendritic Cells: The Ins and Outs of Outcome. J. Immunother. 2006; 29: 465-71.
  4. Одинак М.М., Чирский В.С., Бисага Г.Н. и др. Аутологичные IL-10-модифицированные дендритные клетки в иммунотерапии рассеянного склероза: первый клинический опыт. Клеточная трансплантология и тканевая инженерия 2008; 4: 60-5.
  5. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002; 23: 445-9.
  6. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. 2003; 21: 685-711.
  7. Duan R.S., Link H., Xiao B.G. Long-term effects of IFN-g, IL-10 and TGF-a-modulated dendritic cells on immune response in Lewis rats. J. Clin. Immunol. 2005; 25: 50-6.

Copyright (c) 2019 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 85657 от 21.07.2023 от 11.03.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies